论文部分内容阅读
急性髓性白血病(AML)缓解期患者,接受 HLA相容的同胞骨髓移植(BMT)比常规维持治疗复发机会较少,大部分的患者保持存活和无病征。病人和方法,67例 AML 患者中,40例处于最初的 RI 期,27例为第一次缓解时从 HLA 相容的混合淋巴细胞培养(MLC)无反应的同胞中接受 BMT患者。所有患者均进行严密隔离防护,并口服抗菌药物,制霉菌素和二性霉素 B,兼用新霉素和粘菌素或复方增效磺胺以预防感染。
In patients with acute myeloid leukemia (AML) remission, there is less chance of HLA-compatible sibling bone marrow transplantation (BMT) recurrence than routine maintenance therapy, and most patients remain viable and disease-free. PATIENTS AND METHODS: Of 67 AML patients, 40 were in their initial RI stage and 27 were on first remission with BMT patients from siblings who did not respond to HLA-compatible mixed lymphocyte culture (MLC). All patients were closely guarded isolation and oral antibacterial drugs, nystatin and amphotericin B, both neomycin and colistin or synergistic sulfonamides to prevent infection.